Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ)
CNY 13.24
(0.68%)
CNY 13.24
(0.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -26.56 Million | -52.81 Million | 567.7 Million | 580.38 Million | 534.61 Million | 497.15 Million |
| Net Income | -207.47 Million | -266.2 Million | 380.56 Million | 725.36 Million | 779.9 Million | 668.9 Million |
| Depreciation & Amortization | 84.7 Million | 92.19 Million | 94.51 Million | 92.61 Million | 87.98 Million | 83.15 Million |
| Deferred income taxes | -2.25 Million | 316.41 Thousand | -2.19 Million | -5.83 Million | -3.47 Million | 3.73 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 117.96 Million | 128.05 Million | 107.11 Million | -230.73 Million | -348.06 Million | -241.73 Million |
| Other non-cash items | 7.92 Million | -6.85 Million | -14.48 Million | -6.86 Million | 14.79 Million | -13.16 Million |
| Investing Cash Flow | 11.56 Million | -438.91 Million | -563.02 Million | -215.73 Million | -294.38 Million | -141.77 Million |
| Investments in PPE | -129.31 Million | -150.45 Million | -133.76 Million | -199.68 Million | -169.01 Million | -95.84 Million |
| Acquisitions | 592.1 Thousand | 884.26 Thousand | 942.06 Thousand | 199.69 Million | -7.59 Million | -62.09 Million |
| Investment purchases | -3.18 Billion | -3.55 Billion | -1.53 Billion | -376 Million | -513 Million | -2.74 Billion |
| Sales/Maturities of investments | 3.32 Billion | 3.26 Billion | 1.1 Billion | 359.93 Million | 394.34 Million | 2.73 Billion |
| Other Investing Activities | 140.88 Million | 0.65 | 0.64 | -199.68 Million | 884 Thousand | 25.94 Million |
| Financing Cash Flow | 291.17 Million | 75.91 Million | -209.73 Million | -182.82 Million | -124.71 Million | -15.45 Million |
| Debt repayment | -89 Million | -45 Million | -20 Million | -22.43 Million | -8 Million | -15 Million |
| Dividends payments | -1.12 Million | -92.81 Million | -185.63 Million | -204.19 Million | -111.37 Million | -488.11 Thousand |
| Common Stock Repurchased | - | - | -1.6 Million | -70 Thousand | - | - |
| Common Stock Issuance | - | - | 1.6 Million | - | - | - |
| Other Financing Activities | 203.29 Million | 214.1 Million | -3.98 Million | 22.43 Million | 14.07 Thousand | 37.12 Thousand |
| Accounts receivables | 53.45 Million | 262.96 Million | 363.44 Million | 110.97 Million | -346.71 Million | -149.7 Million |
| Accounts payables | 93.18 Million | -133.44 Million | -281.02 Million | -393.7 Million | 48.21 Million | -70.16 Million |
| Inventory | -26.41 Million | -1.78 Million | 26.89 Million | 57.81 Million | -46.08 Million | -25.59 Million |
| Other working capital | -7.34 Million | 316.41 Thousand | -2.19 Million | -5.83 Million | -3.47 Million | -216.13 Million |
| Cash at beginning of period | 760.67 Million | 1.16 Billion | 1.36 Billion | 1.18 Billion | 1.06 Billion | 728.69 Million |
| Cash at end of period | 1.03 Billion | 760.67 Million | 1.16 Billion | 1.36 Billion | 1.18 Billion | 1.06 Billion |
| Capital Expenditure | -129.31 Million | -150.45 Million | -133.76 Million | -199.68 Million | -169.01 Million | -95.84 Million |
| Effect of forex changes on cash | -1.19 Million | 15.59 Million | -19.42 Thousand | -61.62 Thousand | 15.42 Thousand | 44.87 Thousand |
| Net cash flow / Change in cash | 274.96 Million | -400.22 Million | -205.07 Million | 181.75 Million | 115.53 Million | 339.98 Million |
| Free Cash Flow | -155.88 Million | -203.26 Million | 433.94 Million | 380.7 Million | 365.59 Million | 401.31 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 44.04 Million | 31.54 Million | -207.47 Million | 36.12 Million | -26.2 Million | -89.86 Million |
| Depreciation & Amortization | 22.97 Million | 22.97 Million | 84.7 Million | 84.7 Million | -43.79 Million | 22.6 Million |
| Deferred income taxes | - | - | -2.25 Million | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 117.96 Million | 19.69 Million | -130.52 Million | 130.52 Million |
| Other non-cash items | 83.01 Million | 166.84 Million | 7.92 Million | -157.68 Million | 287.26 Million | -48.63 Million |
| Investing Cash Flow | -226.68 Million | -50.45 Million | 11.56 Million | 117.16 Million | -74.07 Million | -96.45 Million |
| Investments in PPE | -37.4 Million | -43.11 Million | -129.31 Million | -44.51 Million | -35.99 Million | -37.1 Million |
| Acquisitions | 718.31 Thousand | - | 592.1 Thousand | 89.17 Thousand | 107 Thousand | 15.92 Thousand |
| Investment purchases | -1.28 Billion | -745 Million | -3.18 Billion | -555 Million | -913 Million | -805 Million |
| Sales/Maturities of investments | 1.09 Billion | 737.66 Million | 3.32 Billion | 716.58 Million | 874.81 Million | 745.63 Million |
| Other Investing Activities | 718.31 Thousand | -7.33 Million | 140.88 Million | 161.67 Million | 0.17 | 0.59 |
| Financing Cash Flow | -15.43 Million | -30.96 Million | 291.17 Million | 123.98 Million | 155.16 Million | -8.4 Million |
| Debt repayment | -14 Million | -30 Million | -89 Million | -45.04 Million | -30 Million | -6.71 Million |
| Dividends payments | -256.53 Thousand | -437.94 Thousand | -1.12 Million | -72.96 Thousand | -324.78 Thousand | -442.8 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 274.45 Thousand | -530.98 Thousand | 203.29 Million | 169.1 Million | 185.48 Million | -1.24 Million |
| Accounts receivables | - | - | 53.45 Million | 53.45 Million | -141.74 Million | 141.74 Million |
| Accounts payables | - | - | 93.18 Million | - | -2 Million | 2 Million |
| Inventory | - | - | -26.41 Million | -26.41 Million | 11.21 Million | -11.21 Million |
| Other working capital | - | - | -7.34 Million | -7.34 Million | 2 Million | -2 Million |
| Cash at beginning of period | 1.16 Billion | 1.03 Billion | 760.67 Million | 814.24 Million | 651.54 Million | 733.91 Million |
| Cash at end of period | 1.03 Billion | 1.15 Billion | 1.03 Billion | 1.03 Billion | 814.24 Million | 651.54 Million |
| Capital Expenditure | -37.4 Million | -43.11 Million | -129.31 Million | -44.51 Million | -35.99 Million | -37.1 Million |
| Effect of forex changes on cash | 3.11 Million | 727.93 Thousand | -1.19 Million | -2.58 Million | -5.12 Million | 7.85 Million |
| Net cash flow / Change in cash | -133.19 Million | 117.69 Million | 274.96 Million | 221.4 Million | 162.69 Million | -82.37 Million |
| Free Cash Flow | 66.68 Million | 155.27 Million | -155.88 Million | -61.67 Million | 50.73 Million | -22.46 Million |
WILLAMAGOR
3532
HAT
UBQ
AEE
GYANDEV